{"data":[{"accessionNo":"0002012383-26-003764","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock","eventDate":"2026-09-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":9892226,"percentOfClass":5.1,"filedAt":"2026-10-27","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0001140361-26-033404","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-08-13","reportingPerson":"Henry R. Kravis","reportingCik":null,"personType":"IN","sharesOwned":9232739,"percentOfClass":4.7,"filedAt":"2026-08-17","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0001140361-26-033404","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-08-13","reportingPerson":"George R. Roberts","reportingCik":null,"personType":"IN","sharesOwned":9232739,"percentOfClass":4.7,"filedAt":"2026-08-17","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0001140361-26-033404","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-08-13","reportingPerson":"KKR Group Holdings Corp.","reportingCik":null,"personType":"CO","sharesOwned":9232739,"percentOfClass":4.7,"filedAt":"2026-08-17","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0001140361-26-033404","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-08-13","reportingPerson":"KKR Management LLP","reportingCik":null,"personType":"PN","sharesOwned":9232739,"percentOfClass":4.7,"filedAt":"2026-08-17","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0001140361-26-033404","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-08-13","reportingPerson":"KKR Group Co. Inc.","reportingCik":null,"personType":"CO","sharesOwned":9232739,"percentOfClass":4.7,"filedAt":"2026-08-17","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0001140361-26-033404","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-08-13","reportingPerson":"KKR & Co. Inc.","reportingCik":null,"personType":"CO","sharesOwned":9232739,"percentOfClass":4.7,"filedAt":"2026-08-17","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0001140361-26-033404","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-08-13","reportingPerson":"KKR Group Partnership L.P.","reportingCik":null,"personType":"PN","sharesOwned":9232739,"percentOfClass":4.7,"filedAt":"2026-08-17","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0001140361-26-033404","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-08-13","reportingPerson":"KKR Genetic Disorder GP LLC","reportingCik":null,"personType":"OO","sharesOwned":8260971,"percentOfClass":4.2,"filedAt":"2026-08-17","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0001140361-26-033404","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-08-13","reportingPerson":"KKR Genetic Disorder L.P.","reportingCik":"0001780408","personType":"PN","sharesOwned":8260971,"percentOfClass":4.2,"filedAt":"2026-08-17","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Spokes, Andrew J. M.","reportingCik":null,"personType":"HC,IN","sharesOwned":10743063,"percentOfClass":5.5,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Warren, John R.","reportingCik":null,"personType":"HC,IN","sharesOwned":10743063,"percentOfClass":5.5,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Wehrly, Mark C.","reportingCik":null,"personType":"HC,IN","sharesOwned":10743063,"percentOfClass":5.5,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Management, L.L.C.","reportingCik":null,"personType":"IA,OO","sharesOwned":10743063,"percentOfClass":5.5,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Dapice Joshua J.","reportingCik":null,"personType":"HC,IN","sharesOwned":10743063,"percentOfClass":5.5,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Dunn Hannah E.","reportingCik":null,"personType":"HC,IN","sharesOwned":10743063,"percentOfClass":5.5,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Dreyfuss, Philip D.","reportingCik":null,"personType":"HC,IN","sharesOwned":10743063,"percentOfClass":5.5,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Gehani, Varun N.","reportingCik":null,"personType":"HC,IN","sharesOwned":10743063,"percentOfClass":5.5,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Giauque, Nicolas","reportingCik":null,"personType":"HC,IN","sharesOwned":10743063,"percentOfClass":5.5,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Husen, Avner A.","reportingCik":null,"personType":"HC,IN","sharesOwned":10743063,"percentOfClass":5.5,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Kim, David T.","reportingCik":null,"personType":"HC,IN","sharesOwned":10743063,"percentOfClass":5.5,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Linn, Michael G.","reportingCik":null,"personType":"HC,IN","sharesOwned":10743063,"percentOfClass":5.5,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Luo Patrick (Cheng)","reportingCik":null,"personType":"HC,IN","sharesOwned":10743063,"percentOfClass":5.5,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Roberts, Jr., Thomas G.","reportingCik":null,"personType":"HC,IN","sharesOwned":10743063,"percentOfClass":5.5,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Saito Edric C.","reportingCik":null,"personType":"HC,IN","sharesOwned":10743063,"percentOfClass":5.5,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Short Daniel S.","reportingCik":null,"personType":"HC,IN","sharesOwned":10743063,"percentOfClass":5.5,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Healthcare Partners (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Institutional Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Institutional Partners II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Institutional Partners III, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Four Crossings Institutional Partners V, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Offshore Investors II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital (AM) Investors, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital F5 Master I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Healthcare Partners Master, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Partners, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Institutional (GP) V, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000369","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon F5 (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-03","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0002012383-26-002210","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":9733762,"percentOfClass":4.96,"filedAt":"2026-07-27","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-26-003237","formType":"SCHEDULE 13D/A","amendmentNo":12,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-07-09","reportingPerson":"Shabet Rose Sharon","reportingCik":"0001711393","personType":"IN","sharesOwned":9792219,"percentOfClass":5,"filedAt":"2026-07-10","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-26-003237","formType":"SCHEDULE 13D/A","amendmentNo":12,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-07-09","reportingPerson":"HALVORSEN OLE ANDREAS","reportingCik":"0001133006","personType":"IN","sharesOwned":9792219,"percentOfClass":5,"filedAt":"2026-07-10","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-26-003237","formType":"SCHEDULE 13D/A","amendmentNo":12,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-07-09","reportingPerson":"Viking Global Opportunities Illiquid Investments Sub-Master LP","reportingCik":"0001629482","personType":"PN","sharesOwned":9792219,"percentOfClass":5,"filedAt":"2026-07-10","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-26-003237","formType":"SCHEDULE 13D/A","amendmentNo":12,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-07-09","reportingPerson":"Viking Global Opportunities Portfolio GP LLC","reportingCik":"0001629472","personType":"OO","sharesOwned":9792219,"percentOfClass":5,"filedAt":"2026-07-10","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-26-003237","formType":"SCHEDULE 13D/A","amendmentNo":12,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-07-09","reportingPerson":"Viking Global Opportunities GP LLC","reportingCik":"0001629476","personType":"OO","sharesOwned":9792219,"percentOfClass":5,"filedAt":"2026-07-10","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-26-003237","formType":"SCHEDULE 13D/A","amendmentNo":12,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-07-09","reportingPerson":"Viking Global Opportunities Parent GP LLC","reportingCik":"0001886738","personType":"OO","sharesOwned":9792219,"percentOfClass":5,"filedAt":"2026-07-10","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-26-003237","formType":"SCHEDULE 13D/A","amendmentNo":12,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-07-09","reportingPerson":"VIKING GLOBAL INVESTORS LP","reportingCik":"0001103804","personType":"PN","sharesOwned":9792219,"percentOfClass":5,"filedAt":"2026-07-10","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Roberts, Jr., Thomas G.","reportingCik":null,"personType":"IN","sharesOwned":10226063,"percentOfClass":5.2,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Dapice Joshua J.","reportingCik":null,"personType":"IN","sharesOwned":10226063,"percentOfClass":5.2,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Dreyfuss, Philip D.","reportingCik":null,"personType":"IN","sharesOwned":10226063,"percentOfClass":5.2,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Dunn Hannah E.","reportingCik":null,"personType":"IN","sharesOwned":10226063,"percentOfClass":5.2,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Gehani, Varun N.","reportingCik":null,"personType":"IN","sharesOwned":10226063,"percentOfClass":5.2,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Giauque, Nicolas","reportingCik":null,"personType":"IN","sharesOwned":10226063,"percentOfClass":5.2,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Husen, Avner A.","reportingCik":null,"personType":"IN","sharesOwned":10226063,"percentOfClass":5.2,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Kim, David T.","reportingCik":null,"personType":"IN","sharesOwned":10226063,"percentOfClass":5.2,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Linn, Michael G.","reportingCik":null,"personType":"IN","sharesOwned":10226063,"percentOfClass":5.2,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Luo Patrick (Cheng)","reportingCik":null,"personType":"IN","sharesOwned":10226063,"percentOfClass":5.2,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Saito Edric C.","reportingCik":null,"personType":"IN","sharesOwned":10226063,"percentOfClass":5.2,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Short Daniel S.","reportingCik":null,"personType":"IN","sharesOwned":10226063,"percentOfClass":5.2,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Spokes, Andrew J. M.","reportingCik":null,"personType":"IN","sharesOwned":10226063,"percentOfClass":5.2,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Warren, John R.","reportingCik":null,"personType":"IN","sharesOwned":10226063,"percentOfClass":5.2,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Wehrly, Mark C.","reportingCik":null,"personType":"IN","sharesOwned":10226063,"percentOfClass":5.2,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Farallon Partners, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":10023341,"percentOfClass":5.1,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Farallon Healthcare Partners (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":5918914,"percentOfClass":3,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Farallon Healthcare Partners Master, L.P.","reportingCik":null,"personType":"PN","sharesOwned":5918914,"percentOfClass":3,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Farallon Capital Offshore Investors II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1869577,"percentOfClass":1,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Farallon Capital Institutional Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":922612,"percentOfClass":0.5,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Farallon Capital Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":728238,"percentOfClass":0.4,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Farallon F5 (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":202722,"percentOfClass":0.1,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Farallon Capital Institutional Partners II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":167053,"percentOfClass":0.1,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Farallon Capital Institutional Partners III, L.P.","reportingCik":null,"personType":"PN","sharesOwned":145089,"percentOfClass":0.1,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Four Crossings Institutional Partners V, L.P.","reportingCik":null,"personType":"PN","sharesOwned":171156,"percentOfClass":0.1,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Farallon Capital (AM) Investors, L.P.","reportingCik":null,"personType":"PN","sharesOwned":100702,"percentOfClass":0.1,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Farallon Capital F5 Master I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":202722,"percentOfClass":0.1,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000908834-26-000252","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-05-22","reportingPerson":"Farallon Institutional (GP) V, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":171156,"percentOfClass":0.1,"filedAt":"2026-05-29","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0001274173-26-000133","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001743881","issuerName":"BRIDGEBIO PHARMA, INC.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"JANUS HENDERSON GROUP PLC","reportingCik":null,"personType":"HC","sharesOwned":13179013,"percentOfClass":6.8,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-26-001499","formType":"SCHEDULE 13D/A","amendmentNo":11,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"VIKING GLOBAL INVESTORS LP","reportingCik":"0001103804","personType":"PN","sharesOwned":11842434,"percentOfClass":6.1,"filedAt":"2026-04-02","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-26-001499","formType":"SCHEDULE 13D/A","amendmentNo":11,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Viking Global Opportunities Parent GP LLC","reportingCik":"0001886738","personType":"OO","sharesOwned":11842434,"percentOfClass":6.1,"filedAt":"2026-04-02","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-26-001499","formType":"SCHEDULE 13D/A","amendmentNo":11,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"HALVORSEN OLE ANDREAS","reportingCik":"0001133006","personType":"IN","sharesOwned":11842434,"percentOfClass":6.1,"filedAt":"2026-04-02","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-26-001499","formType":"SCHEDULE 13D/A","amendmentNo":11,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Shabet Rose Sharon","reportingCik":"0001711393","personType":"IN","sharesOwned":11842434,"percentOfClass":6.1,"filedAt":"2026-04-02","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-26-001499","formType":"SCHEDULE 13D/A","amendmentNo":11,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Viking Global Opportunities Illiquid Investments Sub-Master LP","reportingCik":"0001629482","personType":"PN","sharesOwned":11842434,"percentOfClass":6.1,"filedAt":"2026-04-02","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-26-001499","formType":"SCHEDULE 13D/A","amendmentNo":11,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Viking Global Opportunities GP LLC","reportingCik":"0001629476","personType":"OO","sharesOwned":11842434,"percentOfClass":6.1,"filedAt":"2026-04-02","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-26-001499","formType":"SCHEDULE 13D/A","amendmentNo":11,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Viking Global Opportunities Portfolio GP LLC","reportingCik":"0001629472","personType":"OO","sharesOwned":11842434,"percentOfClass":6.1,"filedAt":"2026-04-02","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000102909-26-000828","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001743881","issuerName":"Bridgebio Pharma Inc","ticker":"BBIO","cusip":"10806X102","securityClass":"Common Stock","eventDate":"2026-03-13","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-03-26","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-26-000914","formType":"SCHEDULE 13D/A","amendmentNo":10,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-02-12","reportingPerson":"Shabet Rose Sharon","reportingCik":"0001711393","personType":"IN","sharesOwned":13026367,"percentOfClass":6.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-26-000914","formType":"SCHEDULE 13D/A","amendmentNo":10,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-02-12","reportingPerson":"VIKING GLOBAL INVESTORS LP","reportingCik":"0001103804","personType":"PN","sharesOwned":13026367,"percentOfClass":6.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-26-000914","formType":"SCHEDULE 13D/A","amendmentNo":10,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-02-12","reportingPerson":"Viking Global Opportunities Parent GP LLC","reportingCik":"0001886738","personType":"OO","sharesOwned":13026367,"percentOfClass":6.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-26-000914","formType":"SCHEDULE 13D/A","amendmentNo":10,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-02-12","reportingPerson":"Viking Global Opportunities GP LLC","reportingCik":"0001629476","personType":"OO","sharesOwned":13026367,"percentOfClass":6.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-26-000914","formType":"SCHEDULE 13D/A","amendmentNo":10,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-02-12","reportingPerson":"Viking Global Opportunities Portfolio GP LLC","reportingCik":"0001629472","personType":"OO","sharesOwned":13026367,"percentOfClass":6.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-26-000914","formType":"SCHEDULE 13D/A","amendmentNo":10,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-02-12","reportingPerson":"Viking Global Opportunities Illiquid Investments Sub-Master LP","reportingCik":"0001629482","personType":"PN","sharesOwned":13026367,"percentOfClass":6.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-26-000914","formType":"SCHEDULE 13D/A","amendmentNo":10,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-02-12","reportingPerson":"HALVORSEN OLE ANDREAS","reportingCik":"0001133006","personType":"IN","sharesOwned":13026367,"percentOfClass":6.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-26-000914","formType":"SCHEDULE 13D/A","amendmentNo":10,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-02-12","reportingPerson":"Ott David C.","reportingCik":"0001621842","personType":"IN","sharesOwned":13026367,"percentOfClass":6.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0001274173-26-000074","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BRIDGEBIO PHARMA, INC.","ticker":"BBIO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"JANUS HENDERSON GROUP PLC","reportingCik":null,"personType":"HC","sharesOwned":11000457,"percentOfClass":5.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-25-004059","formType":"SCHEDULE 13D/A","amendmentNo":9,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-11-14","reportingPerson":"Viking Global Opportunities Illiquid Investments Sub-Master LP","reportingCik":"0001629482","personType":"PN","sharesOwned":15893934,"percentOfClass":8.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-25-004059","formType":"SCHEDULE 13D/A","amendmentNo":9,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-11-14","reportingPerson":"Viking Global Opportunities GP LLC","reportingCik":"0001629476","personType":"OO","sharesOwned":15893934,"percentOfClass":8.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-25-004059","formType":"SCHEDULE 13D/A","amendmentNo":9,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-11-14","reportingPerson":"HALVORSEN OLE ANDREAS","reportingCik":"0001133006","personType":"IN","sharesOwned":15893934,"percentOfClass":8.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-25-004059","formType":"SCHEDULE 13D/A","amendmentNo":9,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-11-14","reportingPerson":"Ott David C.","reportingCik":"0001621842","personType":"IN","sharesOwned":15893934,"percentOfClass":8.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-25-004059","formType":"SCHEDULE 13D/A","amendmentNo":9,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-11-14","reportingPerson":"Shabet Rose Sharon","reportingCik":"0001711393","personType":"IN","sharesOwned":15893934,"percentOfClass":8.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-25-004059","formType":"SCHEDULE 13D/A","amendmentNo":9,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-11-14","reportingPerson":"Viking Global Opportunities Portfolio GP LLC","reportingCik":"0001629472","personType":"OO","sharesOwned":15893934,"percentOfClass":8.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-25-004059","formType":"SCHEDULE 13D/A","amendmentNo":9,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-11-14","reportingPerson":"VIKING GLOBAL INVESTORS LP","reportingCik":"0001103804","personType":"PN","sharesOwned":15893934,"percentOfClass":8.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-25-004059","formType":"SCHEDULE 13D/A","amendmentNo":9,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-11-14","reportingPerson":"Viking Global Opportunities Parent GP LLC","reportingCik":"0001886738","personType":"OO","sharesOwned":15893934,"percentOfClass":8.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000080255-25-000848","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001743881","issuerName":"BridgeBio Oncology Therapeutics Inc","ticker":"BBIO","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-09-30","reportingPerson":"T. Rowe Price Associates, Inc.","reportingCik":null,"personType":"IA","sharesOwned":885042,"percentOfClass":1.1,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-25-004059","formType":"SCHEDULE 13D/A","amendmentNo":9,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-11-14","reportingPerson":"Viking Global Opportunities Liquid Portfolio Sub-Master LP","reportingCik":"0001629483","personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-25-004059","formType":"SCHEDULE 13D/A","amendmentNo":9,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-11-14","reportingPerson":"Viking Long Fund GP LLC","reportingCik":"0001621607","personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-25-004059","formType":"SCHEDULE 13D/A","amendmentNo":9,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-11-14","reportingPerson":"VIKING GLOBAL PERFORMANCE LLC","reportingCik":"0001132625","personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-25-004059","formType":"SCHEDULE 13D/A","amendmentNo":9,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-11-14","reportingPerson":"Viking Global Equities II LP","reportingCik":"0001413378","personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-25-004059","formType":"SCHEDULE 13D/A","amendmentNo":9,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-11-14","reportingPerson":"Viking Long Fund Master Ltd.","reportingCik":"0001621596","personType":"CO","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"},{"accessionNo":"0000905148-25-004059","formType":"SCHEDULE 13D/A","amendmentNo":9,"issuerCik":"0001743881","issuerName":"BridgeBio Pharma, Inc.","ticker":"BBIO","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-11-14","reportingPerson":"Viking Global Equities Master Ltd.","reportingCik":"0001759530","personType":"CO","sharesOwned":0,"percentOfClass":0,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/bbio"}],"updatedAt":"2026-10-29T11:51:07.274Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/bbio","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}